Dr. Mothaffar Rimawi, MD
Claim this profileBaylor College of Medicine
Studies Breast Cancer
Studies Skin Cancer
11 reported clinical trials
23 drugs studied
Area of expertise
1Breast Cancer
HER2 positive
ER positive
Stage IV
2Skin Cancer
HER2 positive
ER positive
ER negative
Affiliated Hospitals
Clinical Trials Mothaffar Rimawi, MD is currently running
Chemotherapy Response Prediction
for Breast Cancer
The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving chemotherapy prior to surgery.
Recruiting1 award Phase 2
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
More about Mothaffar Rimawi, MD
Clinical Trial Related5 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Mothaffar Rimawi, MD has experience with
- Paclitaxel
- Pertuzumab
- Trastuzumab
- Placebo
- Tucatinib
- TAA-specific CTLs
Breakdown of trials Mothaffar Rimawi, MD has run
Breast Cancer
Breast cancer
Uterine Tumors
Lobular Carcinoma in Situ
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mothaffar Rimawi, MD specialize in?
Mothaffar Rimawi, MD focuses on Breast Cancer and Skin Cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are ER positive.
Is Mothaffar Rimawi, MD currently recruiting for clinical trials?
Yes, Mothaffar Rimawi, MD is currently recruiting for 3 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Mothaffar Rimawi, MD has studied deeply?
Yes, Mothaffar Rimawi, MD has studied treatments such as Paclitaxel, Pertuzumab, Trastuzumab.
What is the best way to schedule an appointment with Mothaffar Rimawi, MD?
Apply for one of the trials that Mothaffar Rimawi, MD is conducting.
What is the office address of Mothaffar Rimawi, MD?
The office of Mothaffar Rimawi, MD is located at: Baylor College of Medicine, Houston, Texas 77030 United States. This is the address for their practice at the Baylor College of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.